Good News Send Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) Into a Frenzy

[[tagnumber 0]][[tagnumber 1]]The shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) are in a trading frenzy ever since the start of the new session today following an optimistic press release concerning an antibody construct associated with actinium–225 utilizing the proprietary alpha particle immunotherapy technology platform.[[tagnumber 2]] [[tagnumber 0]]As a result, ATNM is soaring high, showing no signs of slowing down. Half on hour into today‘s session, ATNM is up 28% from the previous close, traded at $2.55 per share on a crazy volume which has already greatly surpassed the 30–day average of 1.3 million.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]We have yet to see how the implementation of the successfully tested antibody construct into the company‘s clinical trial will impact the potential success of the latter, yet it will take a while ATNM has reached the NDA stage. And until a product candidate has been cleared for commercial use, a biotech‘s principal source of funds will inevitably relate to a mixture of debt and equity financing.[[tagnumber 2]] [[tagnumber 0]]Considering the shortage of cash in a time where there are no fresh cash flows going into the business, taking out new loans will hardly come as a surprise. The same goes for issuing more stock and attracting new stockholders to inject fresh capital.[[tagnumber 2]] [[tagnumber 0]]Actinium Pharmaceuticals‘s most recent developments could give the stock a breath of fresh air, especially since the stock has been struggling on the charts for a whole year now and even crashed to a 52–week low last Monday. By the looks of it, the situation is shaping up quite differently this Monday and ATNM looks poised to get a breath of fresh air. Whether this will help to buck the negative trend will depend upon a) what the next corporate update will bring to the table and b) how long investors will have to wait for it.[[tagnumber 2]]